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Summary
 
Primary infection with virus can stimulate a vigorous cytotoxic T cell response. The magnitude
of the antigen-specific component versus the bystander component of a primary T cell re-
sponse remains controversial. In this study, we have used tetrameric major histocompatibility
complex–peptide complexes to directly visualize antigen-specific cluster of differentration
(CD)8
 
1
 
 T cells during the primary immune response to Epstein-Barr virus (EBV) infection in
humans. We show that massive expansion of activated, antigen-specific T cells occurs during
the primary response to this virus. In one individual, T cells specific for a single EBV epitope
comprised 44% of the total CD8
 
1
 
 T cells within peripheral blood. The majority of the anti-
gen-specific cells had an activated/memory phenotype, with expression of human histocom-
patibility leukocyte antigen (HLA) DR, CD38, and CD45RO, downregulation of CD62 leu-
kocyte (CD62L), and low levels of expression of CD45RA. After recovery from AIM, the
frequency of antigen-specific T cells fell in most donors studied, although populations of anti-
gen-specific cells continued to be easily detectable for at least 3 yr.
 
P
 
rimary infection with virus can stimulate a vigorous T
cell response, with activation and proliferation of lym-
phocytes at the site of infection (1), within draining lymph
nodes (2), and sometimes also within peripheral blood (3,
4). The extent to which these lymphocytes have been spe-
cifically activated by antigen or nonspecifically activated,
perhaps by cytokines, (bystander activation) is still a matter
of debate. Recent work has suggested that the antigen-spe-
cific component of the primary T cell response to infection
may be greater than was originally suggested (2, 3, 5).
However, progress has been limited by the difficulties of
identifying antigen-specific T cells in vivo. Little is known
about the phenotypic differences between different func-
tional subsets of T cells and it is not yet possible to distin-
guish between antigen-stimulated effector T cells, antigen
specific memory T cells, and bystander-activated T cells on
the basis of cell phenotype. Antibody and PCR techniques
may be used to identify T cells expressing receptors known
to be selected by certain MHC–peptide complexes (2, 5),
but antigen-specific T cells expressing other receptors will
inevitably be missed using these types of approach.
Recently, a novel method of identifying antigen-specific
T lymphocytes has been described (6). Tetrameric MHC–
peptide complexes have been shown to bind stably and
specifically to appropriate MHC-peptide–specific T cells.
This technique may be used both to quantify and to char-
acterize antigen-specific T cells directly. We have exploited
this technique to study antigen-specific T cells during the
primary and early persistent phases of EBV infection in hu-
mans. Infection with this highly immunogenic virus pro-
vides an ideal natural situation in which to study the devel-
opment of a cluster of differentiation (CD)
 
1
 
8
 
1
 
 immune
response in vivo in humans. Primary EBV infection in ado-
lescence or young adulthood may be clinically manifest as
acute infectious mononucleosis (AIM), a disease character-
ized by a striking expansion of CD8
 
1
 
 T cells in peripheral
blood. Resolution of the symptoms is associated with the
return to a normal blood picture and with the establish-
ment of a life-long virus carrier state under the control of
memory T cell surveillance.
EBV is a gamma herpes virus that can establish both la-
tent and fully productive (lytic) infections, involving the
expression of different sets of viral genes (7–9). The B cell
reservoir is the site of virus latency, whereas lytic infections
 
1
 
Abbreviations used in this paper: 
 
AIM, acute infectious mononucleosis; CD,
cluster of differentiation; EBNA, Epstein-Barr nuclear antigen; IM, infec-
tious mononucleosis.
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appear to be focused in epithelial and/or locally infiltrating
B cells in the oropharynx. Most work on CTL control of
EBV infection in humans has concentrated on the response
to latent cycle antigens (10, 11); here, the evidence from
limiting dilution assays in vitro suggests that the frequency
of circulating CD8
 
1
 
 T cells with specificity for given target
epitopes ranges from 1:100 to 1:500 during primary infec-
tion and from 1:500 to 1:2,500 once the long-term virus
carrier state has been established (12). Recently, CTL re-
sponses to lytic cycle antigens have been identified (13–15)
and, certainly during the primary response, their frequen-
cies appear to be at least as high as the latent antigen-spe-
cific reactivities. Even so, if such values from in vitro out-
growth are accurate, then the virus-specific response as a
whole would account for just a minor fraction of the total
CD8
 
1
 
 T cell population in AIM. Somewhat in contrast, a
study of the TCR repertoire used in AIM indicates the
presence of unusually large T cell expansions that can con-
stitute up to 25% of the total CD8
 
1
 
 pool and whose mono-
clonal or oligoclonal pattern of TCR usage implies that
they are antigen driven (3).
In an effort to reconcile these data, we have made tet-
ramers of MHC molecules complexed to defined EBV
peptide epitopes, and used these to identify directly and to
characterize epitope-specific T cells within the primary
T cell response in AIM patients. In selected individuals we
have also used the tetramers to search for epitope-specific
T cells in the circulation between 6 and 37 mo later, after
establishment of the long-term virus carrier state. We chose
to study the response to two immunodominant epitopes
from EBV lytic cycle proteins (an HLA A2–restricted
epitope in BMLF1 and an HLA B8–restricted epitope in
BZLF1) and to one immunodominant epitope from an
EBV latent cycle protein (an HLA B8–restricted epitope in
Epstein-Barr nuclear antigen (EBNA) 3A). We went on to
analyze the phenotype of the antigen-specific cells, looking
at expression of known markers of activation (HLA DR,
CD38, downregulation of CD62 leukocyte [CD62L]),
memory (CD45RO), and late differentiation (CD57) in
the T cell lineage. We demonstrate massive expansion of
activated, antigen-specific CD8
 
1
 
 T cells during the primary
immune response to EBV and show that antigen-specific
CD8
 
1
 
 T cells persist at relatively high frequencies for at
least 3 yr after primary infection.
 
Materials and Methods
 
Patients.
 
10 HLA A2–positive individuals and three HLA
B8–positive individuals with recent onset of AIM and a positive
EBV-specific latex agglutination test (Oxoid, Basingstoke, UK)
were studied. Samples of peripheral blood were taken as soon as
the diagnosis of AIM was confirmed. Further samples were taken
from selected donors 6–37 mo later, long after full recovery from the
clinical illness.
 
Normal Individuals.
 
Samples of peripheral blood were also
taken from HLA A2
 
1
 
 and HLA B8
 
1
 
 normal healthy adult indi-
viduals of known serological status with respect to anti-EBV anti-
bodies.
 
Isolation and Fractionation of Lymphocyte Preparations.
 
Peripheral
blood was diluted with an equal volume of RPMI. PBMCs were
separated using Ficoll-Hypaque density gradient centrifugation
and cryopreserved within 3 h of venesection.
 
Tissue Typing.
 
Class I tissue typing was performed on lympho-
cytes using classical serological methods.
 
Synthesis of MHC–Peptide Tetrameric Complexes.
 
Soluble pep-
tide–MHC tetramers were produced using a similar method to
that described by Altman et al. (6). Recombinant class I heavy
chain (HLA A2 and HLA B8) or 
 
b
 
2 microglobulin was produced
in 
 
Escherichia coli
 
 cells transformed with the relevant expression
plasmids. Expression of class I heavy chain was limited to the ex-
tracellular domain only and the sequence of this domain was
modified by the addition of a substrate sequence for BirA biotiny-
lation at the COOH terminus. HLA A2 and HLA B8 complexes
were folded in vitro using 30 mg of heavy chain protein, 25 mg
of 
 
b
 
2 microglobulin, and 10 mg of synthetic peptide. The HLA
A2 peptide ligand was GLCTLVAML (13, 14; from the EBV
lytic protein BMLF1), and the HLA B8 peptide ligands were
RAKFKQLL (13, 15; from the EBV lytic protein BZLF1) and
FLRGRAYGL (16; from the latent protein EBNA 3A). Protease
inhibitors (2 
 
m
 
g/ml pepstatin, 2 
 
m
 
g/ml leupeptin, and 0.2 mM
phenylmethylsulphonyl fluoride) were used to preserve the pro-
tein. The MHC complexes were biotinylated using purified BirA
enzyme at a concentration of 5 
 
m
 
g/ml, 0.5 mM biotin, and 5
mM ATP. The reaction was incubated at room temperature for
16 h. Typically, levels of biotinylation of 80% were achieved.
The biotinylated MHC–peptide complexes were recovered by
FPLC purification (using buffer containing 20 mM Tris, pH 8.0,
and 50 mM NaCl) and ion exchange chromatography (0–0.5 M
NaCl gradient). Tetramers were made by mixing biotinylated
protein complex with streptavidin-PE (Sigma Chemical Co.) at a
molar ratio of 4:1.
 
Cell Staining.
 
2 
 
3
 
 10
 
5
 
 PBMCs were incubated at 4
 
8
 
C for 30
min in 2 
 
m
 
l of a solution of phycoerythrin-labeled tetrameric
complex at a concentration of HLA molecules of 0.5 mg/ml, in
PBS with 0.1% bovine serum albumin and 0.1% sodium azide.
The cells were washed and then incubated at 4
 
8
 
C for a further 30
min in the presence of saturating concentrations of an anti-CD8
monoclonal antibody directly conjugated to Tricolor (Caltag
Labs., South San Francisco, CA) and of one of a panel of mono-
clonal antibodies directly conjugated to FITC. The panel in-
cluded anti-CD45RO (Dako Corp., Carpinteria, CA), anti-
CD45RA (Immunotech, Marseille, France), anti-HLA DR
(Dako Corp.), anti-CD38 (DAKO), anti-CD62L (PharMingen,
San Diego, CA), anti-CD28 (Immunotech), and anti-CD57
(Becton Dickinson, Mountain View, CA). After washing, the
cells were fixed in PBS containing 1% formaldehyde and 1% fetal
calf serum. Samples were analyzed on a Becton Dickinson
FACS
 
Ò
 
 using CELLQuest software.
 
Results
 
Specificity of the HLA–Peptide Tetrameric Complexes.
 
We
made phycoerythrin-labeled tetrameric complexes of HLA
A2 folded with the GLCTLVAML peptide from the EBV
lytic protein BMLF1 (13, 14) and of HLA B8 folded with
the RAKFKQLL epitope from the EBV lytic protein
BZLF1 (13, 15) and with the FLRGRAYGL epitope from
the EBV latent protein EBNA 3A (16).
The HLA A2–GLCTLVAML tetrameric complex stained
HLA A2–restricted GLCTLVAML-specific T cell clones
(Fig. 1 
 
a
 
), but did not stain other HLA A2–restricted clones 
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specific for the HIV gag epitope (SLYNTVATL; Fig. 1 
 
b
 
)
or for the influenza matrix protein epitope (GILGFVFTL;
data not shown). Additional controls confirmed the speci-
ficity of the tetramer staining. Thus the complex did not
stain CD8
 
1
 
 T cells within PBL preparations from healthy
HLA A2–negative individuals (Fig. 1 
 
c
 
) within parallel prep-
arations from HLA A2–negative AIM patients (Fig. 1 
 
d
 
) or
within preparations from healthy HLA A2–positive indi-
viduals who were EBV seronegative (Fig. 1 
 
e
 
).
The specificities of the HLA B8–FLRGRAYGL and the
HLA B8–RAKFKQLL tetrameric complexes were tested
in a similar way. The tetramers stained T cell clones specific
for the appropriate ligand, but not T cell clones specific for
other HLA B8–restricted peptides (data not shown). Nei-
ther of the HLA B8 tetrameric complexes stained T cells
within PBLs taken from HLA B8–negative donors (data
not shown), nor did they stain T cells within PBLs taken
from HLA B8–positive individuals who were EBV seroneg-
ative (data not shown).
 
Frequency of Circulating EBV Epitope-specific T Cells during
Primary EBV Infection.
 
We used the three tetramers to an-
alyze the frequency of circulating CD8
 
1
 
 T cells specific for
immunodominant EBV lytic (GLCTLVAML and RAK-
FKQLL) and latent (FLRGRAYGL) cycle epitopes during
primary EBV infection.
PBLs taken from 10 HLA A2–positive individuals suffer-
ing from recent onset AIM were stained with the phyco-
erythrin-conjugated HLA A2–GLCTLVAML tetrameric
complex and with an antibody to CD8 conjugated to tri-
color. In all HLA A2–positive individuals, a population of
CD8
 
1
 
 T cells clearly stained with the HLA A2–GLCTL-
VAML tetrameric complex. The frequency of tetramer-
reactive T cells in PBL ranged from 0.5 to 6.6% of the
CD8
 
1
 
 T cells in blood in the 10 donors with AIM. In 4 of
Figure 1. Specificity of the HLA
A2–GLCTLVAML tetrameric com-
plex for HLA A2–restricted GLCTL-
VAML-specific T cell clones. An
HLA A2–restricted GLCTLVAML-
specific T cell clone (a), an HLA
A2–restricted SLYNTVATL-spe-
cific T cell clone (b), PBLs from a
normal healthy HLA A2–negative
individual (c), PBLs from an HLA
A2–negative individual with AIM
(d), and PBLs from an HLA A2–
positive, EBV-seronegative individual (e) were stained with phycoeryth-
rin-conjugated HLA A2–GLCTLVAML tetrameric complex and with an
antibody to CD8-conjugated to tricolor.
Figure 2. The frequency of CD81 T cells specific for three epitopes
from EBV within PBLs taken from donors suffering from AIM (a) PBLs
from the two HLA A2–positive donors, IM74 and IM83, suffering from
AIM, were stained with phycoerythrin-conjugated HLA A2–GLCTL-
VAML tetrameric complex and with an antibody to CD8 conjugated to
tricolor. (b) PBLs from HLA B8–positive donors IM70 and IM59, suffer-
ing from AIM, were stained with phycoerythrin-conjugated HLA B8–
RAKFKQLL tetrameric complex and with an antibody to CD8 conju-
gated to tricolor. (c) PBLs from HLA B8–positive donors IM63 and
IM59, suffering from AIM, were stained with phycoerythrin-conjugated
HLA B8–FLRGRAYGL tetrameric complex and with an antibody to
CD8 conjugated to tricolor. In each figure, the number of CD81 T cells
that stain with the tetrameric complex is shown as percent frequency. 
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the 10 donors, the frequency was 
 
.
 
5%. Fig. 2 
 
a
 
 illustrates the
data obtained from patients infectious mononucleosis (IM)74
and IM83 in whom 5.6 and 6.6% of circulating CD8
 
1
 
 T
cells stained with the HLA A2–GLCTLVAML complex.
In a second series, PBLs taken from three HLA B8–posi-
tive individuals suffering from recent onset AIM were
stained with the phycoerythrin-conjugated HLA B8–
RAKFKQLL or HLA B8–FLRGRAYGL tetrameric com-
plex and with an anti-CD8 antibody conjugated to Tri-
color. The frequency of HLA B8–RAKFKQLL–reactive
CD8
 
1
 
 T cells was very high in these donors. Fig. 2 
 
b
 
 shows
that 44 and 40% of CD8
 
1
 
 T cells in PBLs from patients
IM70 and IM59, respectively, stained with this tetrameric
complex. In the third patient, IM63, the level of staining
was 29%. In contrast, the frequency of CD8
 
1
 
 T cells reac-
tive with the HLA B8–FLRGRAYGL tetrameric complex
was relatively low. Fig. 2 
 
c
 
 shows that 1.2 and 2.2% of
CD8
 
1
 
 T cells in PBLs from patients IM63 and IM59, re-
spectively, stained with this complex. Only 0.3% of CD8
 
1
 
T cells from patient IM70 were identified in this way.
FLRGRAYGL is known to be a dominant EBV latent cy-
cle epitope and in donor IM63 we have previously shown
that the T cell response to this epitope dominates the T cell
response to EBV latent cycle antigens (12). Nevertheless in
all three individuals in this study, the frequency of CD8
 
1
 
 T
cells specific for the HLA B8–restricted EBV lytic cycle
epitope (RAKFKQLL) was at least 10-fold greater than the
frequency of cells specific for the HLA B8–restricted latent
cycle epitope (FLRGRAYGL).
At the same time, we again conducted control experi-
ments showing that PBL from HLA-mismatched individu-
als suffering from AIM did not stain with the tetrameric
MHC–peptide complexes (Fig. 1 
 
d
 
 and data not shown).
 
Frequency of Circulating EBV Epitope-specific T Cells in
Postconvalescent AIM Patients.
 
We had access to samples of
peripheral blood taken from two of the HLA A2–positive
patients and all three of the HLA B8–positive patients be-
tween 6 and 37 mo after primary infection with EBV. At
this time all donors had fully recovered from the clinical ill-
ness. The frequency of CD8
 
1
 
 T cells reactive with the
EBV lytic cycle epitopes (GLCTLVAML and RAK-
FKQLL) fell in all the donors studied, although populations
of tetramer-reactive cells remained easily detectable (Fig. 3, 
 
a
 
and 
 
b
 
). Interestingly, the frequency of CD8
 
1
 
 T cells reac-
tive with the EBV latent cycle epitope (FLRGRAYGL)
was similar in the acute and follow-up samples (Fig. 3 
 
c
 
). In
light of these findings, we used the tetrameric complexes to
study the frequency of EBV epitope-specific T cells in
healthy adult donors who were seropositive for EBV, but
gave no history of AIM. Such individuals are likely to have
carried the viral infection for many years. Staining of PBLs
taken from these donors revealed a low but still significant
frequency (usually 
 
,
 
1:200) of tetramer-reactive CD8
 
1
 
lymphocytes in some individuals with the relevant HLA
class I allele (data not shown). Importantly, in control ex-
periments of the kind illustrated in Fig. 1, 
 
c
 
 and 
 
e
 
, we again
showed that PBLs taken from HLA-matched EBV-seroneg-
ative donors or from HLA-mismatched EBV-seropositive
donors gave no staining with the tetrameric complexes
(Fig. 1, 
 
c
 
 and 
 
e
 
, and data not shown).
 
Phenotype of EBV Epitope-specific T Cells during the Primary
T Cell Response In Vivo.
 
The phenotype of the tetramer
reactive cells was analyzed in six individuals suffering from
AIM using three-color FACS
 
Ò
 
 analysis. The results of such
an analysis, in this case involving the HLA A2–GLCTL-
VAML tetramer–reactive cells in patient IM73, are shown
in Fig. 4. The epitope–specific cells had an activated/mem-
ory phenotype; thus the majority expressed the activation
markers HLA DR (Fig. 4 
 
b
 
), and CD38 (17; Fig. 4 
 
c
 
), but
showed downregulation of the lymph node homing recep-
tor CD62L (18; Fig. 4 
 
d
 
), consistent with the finding that
the molecule is downregulated after lymphocyte activation.
Note also that the majority of the tetramer-reactive cells
expressed the CD45RO isoform of CD45 and not the
CD45RA isoform (19; Fig. 4, 
 
e
 
 and 
 
f
 
); in this context,
CD45RO has been proposed as a marker both for recently
activated and for “memory” T cells. CD28, the ligand for
B7, is an important costimulatory molecule that is normally
Figure 3. The frequency of
CD81 T cells specific for three
epitopes from EBV within PBLs
taken from donors suffering from
AIM and from the same donors
at least 6 mo later. PBLs from
HLA A2–positive donors (a) and
HLA B8–positive donors (b and
c) suffering from AIM were
stained with the phycoerythrin-
conjugated HLA A2–GLCTL-
VAML tetrameric complex (a),
the phycoerythrin-conjugated
HLA B8–RAKFKQLL tetrameric
complex (3), or the phycoeryth-
rin-conjugated HLA B8–FLR-
GRAYGL tetrameric complex (c).
The frequency of tetramer-posi-
tive cells within CD81 PBLs taken from donors suffering from AIM is shown in solid bars, and the frequency of tetramer-positive cells within CD81
PBLs taken from the same donors at least 6 mo later is shown in shaded bars.1399 Callan et al.
expressed on the majority of CD41 T cells, but on only
z50% of CD81 T cells (20). This molecule was expressed
on 48% of the epitope-specific cells in patient IM73,
whereas CD57, which has been postulated to be a marker
of terminal T cell differentiation (21), was expressed on
only 2% of that population (Fig. 4 h). Complete results of
the phenotypic analysis of the tetramer-reactive T cells
taken from four HLA A2–positive and two HLA B8–posi-
tive patients with AIM are shown in Table 1. Although
there was some variation between patients, the tetramer-reac-
tive cells were generally CD381, HLA DR1, CD45RO1, and
CD45RA2; levels of CD28 positivity were the most vari-
able.
Phenotype of EBV Epitope-specific T Cells in Postconvalescent
AIM Patients. We were able to compare the phenotype
of the HLA B8–restricted FLRGRAYGL- and RAK-
FKQLL-specific T cells present within peripheral blood
taken from donor IM63 during primary infection and 37 mo
later. During primary infection 44% of CD81 T cells re-
acted with the HLA B8–RAKFKQLL tetrameric complex
(Fig. 5 a). At follow up, still 18% of CD81 T cells reacted
with this complex (Fig. 5 f), though by this time the patient
was completely well and the circulating blood picture was
normal. Compared with the phenotype of HLA B8–RAK-
Table 1. The Frequency of Expression of Cell Surface Glycoproteins by Tetramer-reactive T Cells within PBLs from Six Donors
Suffering from AIM
Donor
A2–GLCTLVAML-specific Cells
B8–RAKFKQLL-
specific Cells
B8–FLRGRAYGL-
specific Cells
74.1 73.1 83.1 72.1 59.1 63.1 59.1 63.1
Percent CD381 98 100 100 58 ND 99 ND 99
Percent HLA DR1 11 63 91 94 78 56 98 80
Percent CD45RO1 64 85 98 100 ND 78 ND 97
Percent CD45RA1 14 6 5 8 ND 5 ND 11
Percent 62L1 2 8 5 4 3 N D2 3N D 5 8
Percent CD281 11 48 85 76 9 14 86 67
Percent CD571 37 2 2 23 ND 25 ND 5
Figure 4. Phenotypic analysis of antigen-specific CD81 T cells in an
individual suffering from AIM. PBLs taken from donor IM73 while he
was suffering from AIM were stained with the phycoerythrin-conjugated
HLA A2–GLCTLVAML tetrameric complex, with a tricolor-conjugated
anti-CD8 antibody, and with one of a panel of antibodies conjugated to
FITC. a shows staining with the HLA A2–GLCTLVAML tetrameric
complex on the x-axis and with CD8 on the y-axis. b–h show staining of
the CD81 T cells with the HLA A2–GLCTLVAML tetrameric complex
on the y-axis and with an antibody specific for HLA DR (b), CD38 (c),
CD62L (d), CD45RO (e), CD45RA (f), CD28 (g), or CD57 (h) on the
x-axis. In each figure, the number of tetramer–reactive T cells that stain
with the particular phenotypic marker is shown as percent frequency.1400 Visualization of Antigen-specific T Cells
FKQLL tetramer–reactive cells during the primary infec-
tion, those cells present in the follow-up bleed showed
lower levels of expression of the activation markers CD38
(Fig. 5, b and g) and HLA DR (data not shown) and higher
levels of the lymph node homing receptor CD62L (data
not shown). There was also an increase in the percentage of
tetramer-reactive cells expressing CD57 (data not shown).
Significantly, there was a clear reduction in the frequency
of expression of CD45RO (Fig. 5, c and h) by the antigen-
specific cells, and an increase in the frequency of expression
of CD45RA (Fig. 5, d and i). Analysis of the HLA B8–
restricted FLRGRAYGL-specific T cells in the same pa-
tient showed a similar fall in the proportion of cells ex-
pressing CD38, HLA DR, and CD45RO and in increase
in the proportion of cells expressing CD62L, CD57, and
CD45RA over the 3 yr since primary infection.
Discussion
Here we have used primary EBV infection in humans as
the model in which to ask what fraction of a primary virus-
induced T cell response is actually made up of virus-specific
(as opposed to coincidentally activated bystander) cells.
Our earlier attempts to address this question using two dif-
ferent approaches have given somewhat conflicting results.
Thus, in vitro cloning experiments suggested that the fre-
quency of T cells specific for a single EBV epitope was no
more than 1:100 (12), whereas a study of TCR usage sug-
gested that the frequency of antigen-specific cells might be
as high as 1:3 (3). In this study, we have used a novel tech-
nique to directly quantify and characterize epitope-specific
T cells during the immune response to EBV. We made tet-
rameric complexes of HLA A2 folded with an EBV lytic
cycle epitope, and of HLA B8 folded with an EBV lytic cy-
cle epitope or an EBV latent cycle epitope. Preliminary
studies showed that the tetrameric complexes stained T cell
clones of the appropriate specificity, but not T cell clones
with different specificities. There were also no nonspecific
reactivities detected on T cells either from EBV-seroposi-
tive but HLA-mismatched donors or from EBV-seronega-
tive HLA matched donors tested as controls. We then went
on to use the tetramers to study the circulating T cells in
HLA A2– or HLA B8–positive AIM patients.
A very high frequency of EBV epitope-specific T cells
was present in peripheral blood in such individuals. Thus
peripheral blood T cells reactive with the HLA A2–restricted
GLCTLVAML peptide from the EBV lytic cycle antigen
BMLF1 were detected in all 10 HLA A2–positive AIM do-
nors tested at levels between 0.5 and 6.6% of CD81 T cells.
Even higher frequencies of T cells reactive with the HLA
B8–restricted RAKFKQLL peptide from the EBV lytic cy-
cle antigen BZLF1 were observed in all three HLA B81
donors studied; in one individual, 44% of circulating CD81
T cells reacted with the HLA B8–RAKFKQLL tetrameric
complex. This represents, in peripheral blood alone, a pop-
ulation of z3 3 109 T cells. In these same three patients,
the frequency of T cells specific for the HLA B8–restricted
FLRGRAYGL peptide from the EBV latent protein EBNA
3A was lower. The relative immunodominance of the
RAKFKQLL (BZLF1) epitope over the FLRGRAYGL
(EBNA 3A) epitope during the primary immune response
to EBV in these donors is consistent with the results of pre-
viously published functional studies (12, 13).
These numbers of EBV antigen-specific cells, measured
directly using tetrameric MHC–peptide complexes, are much
greater than the previously reported precursor frequencies,
estimated using limiting dilution analysis, in a similar group
of patients (12). In donor 59, we can compare the fre-
Figure 5. Comparison of the frequency and phenotype of antigen-spe-
cific CD81 T cells within PBLs taken from a donor suffering from AIM
and 37 mo later. PBLs taken from donor IM63 while he was suffering
from AIM (IM63.1; a–e) and 37 mo later (IM63.3; f–j) were stained with
the phycoerythrin-conjugated HLA B8–RAKFKQLL tetrameric com-
plex, with a tricolor-conjugated anti-CD8 antibody, and with one of a
panel of antibodies conjugated to FITC. Only CD81 T cells were in-
cluded in the phenotypic analysis. Staining with the tetrameric complex is
shown on the y-axis and staining with normal mouse serum (negative
control; a and f), and with an antibody specific for CD38 (b and g),
CD45RO (c and h), CD45RA (d and i), or CD28 (e and j) is shown on the
x-axis. In each figure, the number of tetramer-reactive T cells that stain
with the particular phenotypic marker is shown as percent frequency.1401 Callan et al.
quency of FLRGRAYGL-specific CTLs previously estimated
(12) by in vitro outgrowth in a limiting dilution assay (fre-
quency of 1:358) with that estimated in this study by tet-
ramer staining (frequency of 1:50). The comparison shows
that in vitro outgrowth underestimates the true magnitude
of this latent antigen-induced primary response. We would
anticipate a similar situation for lytic cycle epitope-specific
T cells, although this has not yet been tested rigorously. To
be detectable in a limiting dilution analysis, T cells must be
able to survive and proliferate in culture. T cells in a late
differentiation compartment (perhaps the majority of the
“effector” cells in AIM) are therefore unlikely to be de-
tected using this technique. The proportion of epitope-
specific T cells detectable in a limiting dilution assay may
depend on the “phenotype” of these cells in vivo.
In individuals with AIM, there was some phenotypic
heterogeneity within cell populations, both within an indi-
vidual patient and between patients, perhaps reflecting dif-
ferences in the duration of antigen exposure. However,
certain common themes emerge. The majority of tetramer-
reactive cells had an activated/memory phenotype with
high levels of expression of CD38, HLA DR, and
CD45RO and relatively low levels of expression of CD62L
and of CD45RA. By comparison, expression of CD28, the
ligand for B7, was extremely variable. In patients IM59 and
IM63, we were able to compare CD28 expression on the
relatively small population of HLA B8–FLRGRAYGL tet-
ramer–reactive cells with that of the greatly expanded pop-
ulation of HLA B8–RAKFKQLL tetramer–reactive cells.
In both donors, the proportion of the FLRGRAYGL-spe-
cific T cells expressing CD28 was much higher than the
proportion of the RAKFKQLL-specific T cells expressing
this molecule. This would be consistent with the idea that
CD28 is expressed by naive T cells (22) and T cells in an
early differentiation compartment, but that expression is
lost after multiple rounds of cell division in vivo. It has
been suggested that CD57 expression may also be a marker
for late or terminal differentiation (21). Consistent with
this, analysis of the HLA B8–RAKFKQLL and HLA B8–
FLRGRAYGL tetramer–reactive cells in donor IM59
showed that expression of CD57 was more frequent on the
greatly expanded population of HLA B8–RAKFKQLL–
specific cells.
Although our results clearly show that high numbers of
activated, epitope-specific cells are present in peripheral
blood during the primary response to EBV, the role of
these cells in the control of EBV infection requires further
study. We are currently analyzing the expression of fas
ligand (23) and perforin (24) by tetramer-reactive cells in
order to investigate whether the cells are able to kill target
cells and by what mechanisms of cytotoxicity.
After recovery from AIM, the numbers of epitope-spe-
cific T cells, as estimated by staining with the HLA–peptide
tetrameric complexes, fell in most individuals studied. Here
it is interesting to note that the highly expanded lytic cycle
epitope-specific CTLs were more heavily culled with tran-
sition to the virus-carrier state than the less expanded latent
cycle epitope-specific CTLs; this concept of heavier culling
of the more abundant components of the primary response
was also suggested by the work with functional assays (12).
Nevertheless, populations of both lytic cycle and latent cy-
cle epitope-specific CTLs were still detectable in all the
individuals studied at up to 37 mo after primary EBV infec-
tion. Comparison of the phenotype of the tetramer-reac-
tive T cells in samples of blood taken from donor IM63
during primary infection and 37 mo later revealed interest-
ing changes in cell surface marker expression. The epitope-
specific T cells in the follow-up samples were unexpectedly
heterogenous with respect to expression of markers of acti-
vation and differentiation. Most significantly, CD45RA
was expressed on a substantial subset of tetramer-reactive
CD81 T cells in the follow-up samples, clearly showing
that this CD45 isoform is not a specific marker for “naive”
T cells within the CD81 population. This finding is consis-
tent with the results of a recently published functional
study of the characteristics of a population of CD272
CD81 T cells that expressed CD45RA (25).
In conclusion, this study is the first to demonstrate di-
rectly the magnitude of the specific primary T cell response
induced in vivo by a natural virus infection in humans.
The results show that massive expansion of activated,
epitope-specific CD81 T cells can occur during the pri-
mary immune response to EBV and that a population of
epitope-specific CD81 T cells persists, in peripheral blood,
at a relatively high frequency, for at least 3 yr after primary
infection.
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